Michele Marchetta, Rocio I Lopez, Austin C Hogwood, Georgia Thomas, Gerardina Abbate, Roshanak Markley, Justin M Canada, Antonio Abbate
{"title":"伊伐布雷定降低心率与体位性心动过速综合征患者的症状负担。","authors":"Michele Marchetta, Rocio I Lopez, Austin C Hogwood, Georgia Thomas, Gerardina Abbate, Roshanak Markley, Justin M Canada, Antonio Abbate","doi":"10.1097/FJC.0000000000001705","DOIUrl":null,"url":null,"abstract":"<p><p>Postural Orthostatic Tachycardia Syndrome (POTS) is a clinical syndrome of tachycardia upon standing leading to palpitations, dizziness, chest pain and/or fatigue. An exaggerated norepinephrine response with standing is often present in POTS, but it remains unclear whether the tachycardia is compensatory for a reduced stroke volume or whether the tachycardia is itself causing the symptoms of POTS. We herein report the effects of heart rate lowering with ivabradine, a selective If channel blocker, on symptom burden in patients with POTS. Following ivabradine treatment, there was a significant reduction in the change in heart rate with standing (ΔHR) in all patients from 40 (30-70) to 15 (8-19) bpm (p=0.011), without significant changes in blood pressure. The Malmö score was significantly reduced in all patients from 86 (74-92) to 39 (32-66) (p=0.005). A correlation between ΔHR and the change in Malmö score (R=+0.828; R2 quadratic= 0.635; p<0.001) was present. The parallel improvement in heart rate response and symptoms with ivabradine suggests that the tachycardia response in POTS may not be considered compensatory but rather central to the pathophysiology of POTS symptoms.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Heart Rate Lowering with Ivabradine and Burden of Symptoms in Patients with Postural Orthostatic Tachycardia Syndrome.\",\"authors\":\"Michele Marchetta, Rocio I Lopez, Austin C Hogwood, Georgia Thomas, Gerardina Abbate, Roshanak Markley, Justin M Canada, Antonio Abbate\",\"doi\":\"10.1097/FJC.0000000000001705\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Postural Orthostatic Tachycardia Syndrome (POTS) is a clinical syndrome of tachycardia upon standing leading to palpitations, dizziness, chest pain and/or fatigue. An exaggerated norepinephrine response with standing is often present in POTS, but it remains unclear whether the tachycardia is compensatory for a reduced stroke volume or whether the tachycardia is itself causing the symptoms of POTS. We herein report the effects of heart rate lowering with ivabradine, a selective If channel blocker, on symptom burden in patients with POTS. Following ivabradine treatment, there was a significant reduction in the change in heart rate with standing (ΔHR) in all patients from 40 (30-70) to 15 (8-19) bpm (p=0.011), without significant changes in blood pressure. The Malmö score was significantly reduced in all patients from 86 (74-92) to 39 (32-66) (p=0.005). A correlation between ΔHR and the change in Malmö score (R=+0.828; R2 quadratic= 0.635; p<0.001) was present. The parallel improvement in heart rate response and symptoms with ivabradine suggests that the tachycardia response in POTS may not be considered compensatory but rather central to the pathophysiology of POTS symptoms.</p>\",\"PeriodicalId\":15212,\"journal\":{\"name\":\"Journal of Cardiovascular Pharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cardiovascular Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/FJC.0000000000001705\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FJC.0000000000001705","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Heart Rate Lowering with Ivabradine and Burden of Symptoms in Patients with Postural Orthostatic Tachycardia Syndrome.
Postural Orthostatic Tachycardia Syndrome (POTS) is a clinical syndrome of tachycardia upon standing leading to palpitations, dizziness, chest pain and/or fatigue. An exaggerated norepinephrine response with standing is often present in POTS, but it remains unclear whether the tachycardia is compensatory for a reduced stroke volume or whether the tachycardia is itself causing the symptoms of POTS. We herein report the effects of heart rate lowering with ivabradine, a selective If channel blocker, on symptom burden in patients with POTS. Following ivabradine treatment, there was a significant reduction in the change in heart rate with standing (ΔHR) in all patients from 40 (30-70) to 15 (8-19) bpm (p=0.011), without significant changes in blood pressure. The Malmö score was significantly reduced in all patients from 86 (74-92) to 39 (32-66) (p=0.005). A correlation between ΔHR and the change in Malmö score (R=+0.828; R2 quadratic= 0.635; p<0.001) was present. The parallel improvement in heart rate response and symptoms with ivabradine suggests that the tachycardia response in POTS may not be considered compensatory but rather central to the pathophysiology of POTS symptoms.
期刊介绍:
Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias.
Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.